Catalent Pharma Solutions has completed its acquisition of R.P. Scherer Eberbach, gaining the remaining 49% interest from Gelita AG. Under full Catalent ownership, customers will have access to a wider range of drug development and delivery technologies/services, and a global supply chain network.
 
Catalent and Gelita have had a joint partnership for 60 years. R.P. Scherer Corp. (including the Eberbach joint venture) was founded by the inventor of the rotary die production process for softgel capsules and was sold to Cardinal Health PTS (now Catalent Pharma Solutions).
 
“We are proud of the strong Catalent and R.P. Scherer Eberbach legacy and are very excited about the future of softgel innovation as an important part of the development, delivery and market supply of pharmaceutical and nutraceutical products. This acquisition comes on the heels of on-going extensive investments that Catalent is making in its softgel facilities in Buenos Aires, Argentina; Aprilia, Italy; and St. Petersburg, Florida; and other investments in advanced drug delivery technologies in Germany and the US,” said David Heyens, president of Catalent’s Softgel Business.